前列腺癌
医学
单克隆抗体
抗原
癌症
抗体-药物偶联物
癌症研究
药品
抗体
连接器
结合
前列腺
前列腺特异性抗原
癌细胞
肿瘤科
内科学
免疫学
药理学
数学分析
数学
计算机科学
操作系统
作者
Georges Mjaess,Fouad Aoun,Elie Rassy,Romain Diamand,Simone Albisinni,Thierry Roumeguère
标识
DOI:10.1016/j.clgc.2022.07.009
摘要
Antibody-drug conjugates (ADCs) reflect a new promising approach in prostate cancer, even more so after the practice-changing results in other malignancies, either hematologic or solid. ADCs consist of monoclonal antibodies (mAb) targeted at specific antigens overly expressed on cancer cells compared to normal cells. A cytotoxic payload is attached to the mAb using a stable linker. In prostate cancer, PSMA, STEAP1, TROP2, CD46 and B7-H3 are antigens currently being studied as targets for ADCs. In this paper, we discuss the composition of ADCs and focus on their application and challenges as treatment options in prostate cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI